SCHEMBL22319396

SCHEMBL22319396

COC(=O)c1ccc(CNC(=O)c2cc(-c3cccc(-c4ccncc4)c3)ccc2Oc2ccc(F)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 4/20 0.57
PTGER2 P43116 1/20 0.57
MAPK14 Q16539 3/20 0.53
CYP3A4 P08684 3/20 0.53
ROCK2 O75116 4/20 0.48
ROCK1 Q13464 3/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
PRKACA P17612 1/20 0.48
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
PRKX P51817 1/20 0.48
PRKCQ Q04759 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
MET P08581 1/20 0.48
AURKA O14965 2/20 0.48
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22319390 0.96 PTGER4 (0.61) PTGER4PTGER2MAPK14CYP3A4ROCK2
SCHEMBL22319352 0.91 PTGER4 (0.70) PTGER4PTGER2MAPK14CYP3A4ROCK2
SCHEMBL22319382 0.91 PTGER4 (0.66) PTGER4PTGER2PPARGPPARDPPARA
SCHEMBL22319344 0.91 PTGER4 (0.68) PTGER4PTGER2MAPK14CYP3A4PPARG
SCHEMBL22319358 0.90 PTGER4 (0.65) PTGER4PTGER2MAPK14CYP3A4PPARG
SCHEMBL22319394 0.90 PTGER4 (0.57) PTGER4PTGER2MAPK14CYP3A4
SCHEMBL22319343 0.88 PTGER4 (0.66) PTGER4PTGER2PPARGPPARDPPARA
SCHEMBL31028149 0.87 PTGER4 (0.76) PTGER4PTGER2MAPK14CYP3A4ROCK2
SCHEMBL22319348 0.87 PTGER4 (0.76) PTGER4PTGER2MAPK14CYP3A4ROCK2
SCHEMBL22319400 0.86 PTGER4 (0.69) PTGER4PTGER2PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872226-B2 N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators MEDIBIOFARMA, S.L. (ES) 2024-01-16 US disclosed
US-20220117962-A1 NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS MEDIBIOFARMA, S.L. (ES) 2022-04-21 US disclosed
EP-3693359-A1 NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS MEDIBIOFARMA, S.L. (ES) 2020-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220117962-A1 NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS PTGER2, PTGER4, PTGER1 PTGER4 2/4885PTGER2 1/4885MAPK14 904/4885
US-11872226-B2 N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators PTGER2, PTGER4, PTGER1 PTGER4 2/4885PTGER2 1/4885MAPK14 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.